Zhang Yang

List of Publications by Year
in descending order

18 papers	329 citations	933447 10 h-index	888059 17 g-index
19 all docs	19 docs citations	19 times ranked	424 citing authors

#	Article	IF	Citations
1	HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer. Oncogenesis, 2019, 8, 45.	4.9	38
2	mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. Oncogene, 2019, 38, 622-636.	5.9	37
3	Novel systemic inflammation response index to predict prognosis after thoracoscopic lung cancer surgery: a propensity score€matching study. ANZ Journal of Surgery, 2019, 89, E507-E513.	0.7	31
4	Naples Prognostic Score as a novel prognostic prediction tool in video-assisted thoracoscopic surgery for early-stage lung cancer: a propensity score matching study. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 3679-3697.	2.4	30
5	Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma. Cancers, 2019, 11, 1502.	3.7	27
6	ACSL3€"PAI-1 signaling axis mediates tumor-stroma cross-talk promoting pancreatic cancer progression. Science Advances, 2020, 6, .	10.3	27
7	CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma. Molecular Cancer Therapeutics, 2020, 19, 661-672.	4.1	26
8	Systemic Inflammation Score as a Novel Prognostic Indicator for Patients Undergoing Video-Assisted Thoracoscopic Surgery Lobectomy for Non-Small-Cell Lung Cancer. Journal of Investigative Surgery, 2021, 34, 428-440.	1.3	21
9	Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma. Cancers, 2020, 12, 2310.	3.7	15
10	CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for *FGFR1*-Amplified Lung Cancer. Cancer Research, 2021, 81, 3121-3133.	0.9	12
11	Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in *KRAS* €mutant cancer. EMBO Molecular Medicine, 2021, 13, e13193.	6.9	11
12	Serum uric acid to lymphocyte ratio: A novel prognostic biomarker for surgically resected early-stage lung cancer. A propensity score matching analysis. Clinica Chimica Acta, 2020, 503, 35-44.	1.1	10
13	Malignant pleural mesothelioma co-opts BCL-XL and autophagy to escape apoptosis. Cell Death and Disease, 2021, 12, 406.	6.3	10
14	Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5€²-deoxy-5-fluorocytidine (5€²-DFCR). Journal of Experimental and Clinical Cancer Research, 2021, 40, 138.	8.6	9
15	A Breakthrough Brought about by Targeting KRASG12C: Nonconformity Is Punished. Cancers, 2022, 14, 390.	3.7	9
16	Single-incision versus multiport video-assisted thoracoscopic surgery in the treatment of lung cancer: a systematic review and meta-analysis. Acta Chirurgica Belgica, 2018, 118, 85-93.	0.4	8
17	Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer. Journal of Experimental and Clinical Cancer Research, 2022, 41, 25.	8.6	6
18	Is liposomal bupivacaine superior to standard bupivacaine for pain control following minimally invasive thoracic surgery?. Interactive Cardiovascular and Thoracic Surgery, 2020, 31, 199-203.	1.1	1